ArticleCureus2026
Multidisciplinary Content Validation of the GiriMok Point-of-Care Protocol for Neonatal Cyanotic Congenital Heart Disease.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Neonatal cyanotic congenital heart disease is a time-critical emergency requiring immediate bedside decision-making. Current guidelines lack a validated, comprehensive point-of-care (POC) protocol suitable for frontline clinicians in diverse settings. The GiriMok Protocol was developed to bridge this gap. This study aimed to develop and establish the content validity of the GiriMok POC Protocol through a rigorous four-phase iterative multidisciplinary expert validation process. Methodology This four-phase study comprised two external validation phases and two author-led refinement phases. Phase 1 involved 18 multidisciplinary experts using a 33-parameter mixed-methods instrument. Phase 2 consisted of focused revalidation by five specialists (neonatologists and a pediatric cardiologist) using a 16-item instrument with modified kappa (k*) computation. Phases 3 and 4 involved evidence-referenced enhancements against 2023-2025 guidelines and final quality assurance. Content Validity Index (CVI) was calculated at item (I-CVI) and scale (S-CVI/Ave) levels. Results In total, 18 unique validators participated across 24 episodes. Phase 1 yielded an S-CVI/Ave of 0.927, with all items meeting the I-CVI ≥0.78 threshold and zero safety concerns. Phase 2 achieved perfect scores (S-CVI/Ave = k* = 1.000) following the integration of a 22-item revision agenda. In total, 35 expert-informed corrections resulted in the final publication-ready GiriMok V4.0. Conclusions The GiriMok POC Protocol achieved unanimous multidisciplinary validation. The perfect Phase 2 CVI demonstrates methodological rigor and responsiveness to expert feedback. The protocol is now positioned for prospective clinical evaluation and national dissemination as a neonatal emergency decision-support tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.